Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...

PLYMOUTH MEETING, PA [September 12, 2022] — The National Comprehensive Cancer Network ® (NCCN ®) has published new NCCN Guidelines for Patients ®: Marginal Zone Lymphoma. A cancer of the lymphatic ...

Research at the European Hematology Association featured zanubrutinib as monotherapy and in combination with rituximab, and well as evaluations of biomarkers that signal responses. Zanubrutinib, the ...

Please provide your email address to receive an email when new articles are posted on . In this video, Joshua Brody, MD, discusses results from the ongoing phase 2 MorningSun trial of subcutaneous ...

The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.

This week, the FDA granted priority review to a supplemental new drug application (sNDA) for zanubrutinib (Brukinska) as a treatment option for adults with marginal zone lymphoma who have previously ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib, an investigational novel potent, highly selective, ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda This retrospective cohort study included patients ...

Outcomes in newly diagnosed diffuse large B cell lymphoma presenting with hepatic and/ or renal dysfunction. Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients ...

Please provide your email address to receive an email when new articles are posted on . Targeted therapies have rapidly changed the treatment landscape of indolent non-Hodgkin lymphoma, a heterogenous ...